Jazz Pharmaceuticals (JAZZ) said Friday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for zanidatamab to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer.

The recommendation for the conditional marketing authorization of the investigational monotherapy in the European Union is backed by data from a phase 2b trial of patients previously treated with systemic therapy, according to the biopharmaceutical company.

The European Commission is expected to make a final decision based on the Committee's recommendation, Jazz Pharmaceuticals said.

JAZZ shares were edging 0.6% higher in recent trading.

Price: 109.58, Change: +0.60, Percent Change: +0.55